Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Multi-Center, Dose Response, Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Moderately Active Crohn's Disease

NCT00106314 is registered in ClinicalTrials.gov with Inflabloc Pharmaceuticals as lead sponsor.

NCT NCT00106314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00106314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Multi-Center, Dose Response, Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Moderately Active Crohn's Disease
Lead sponsor
Inflabloc Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2005
Completion date
October 31, 2006
Enrollment
75
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease